Skip to main content

Health condition · Clinically reviewed

Appendix cancer, rare histology, specialist care and why the centre matters.

One or two cases per million a year. Usually found by accident. Almost always best managed at a national peritoneal malignancy centre.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a UK clinician with an interest in peritoneal and neuroendocrine malignancy.

  • 02

    Sourced from guidance

    Checked against PSOGI, ENETS, NICE and UK peritoneal malignancy centre pathways you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including CRS plus HIPEC at Basingstoke and Lu-177 DOTATATE for advanced neuroendocrine disease.

Key facts

Appendix cancer at a glance.

A rare group of tumours with very different biology, from indolent tip NETs to aggressive signet ring adenocarcinoma. The histology drives everything.

  • How rare

    Around 1 to 2 cases per million per year. About 1 percent of appendicectomies for suspected appendicitis reveal an incidental malignancy.

  • Main types

    Neuroendocrine tumour (NET), goblet cell adenocarcinoma, LAMN and HAMN mucinous neoplasms, colonic-type adenocarcinoma and signet ring adenocarcinoma.

  • Most common

    Neuroendocrine tumour, about half of all appendix cancers. Usually picked up incidentally after an appendicectomy for suspected appendicitis.

  • Pseudomyxoma risk

    A LAMN that perforates can seed mucinous cells across the peritoneum, producing pseudomyxoma peritonei (PMP) and the classic jelly belly.

  • Reference centres

    Peritoneal malignancy is treated at UK national centres in Basingstoke and Manchester, with linked EU centres in the Netherlands.

  • Best-case outcome

    Small distal-tip NETs under 1 cm are usually cured by appendicectomy alone. Low-grade PMP after CRS plus HIPEC has 5-year survival of 60 to 90 percent.

Why this guide matters

The histology tells you the plan.

Appendix cancer is a family of diseases, not one. The right operation and the right centre depend on what the pathologist sees.

  • NET is usually curable

    A small, well-differentiated distal NET is often cured by the appendicectomy alone. Larger or invasive NETs need a right hemicolectomy.

  • Mucinous disease can seed the peritoneum

    LAMN and HAMN that perforate can produce pseudomyxoma peritonei. CRS plus HIPEC at a national centre gives the best chance of long control.

  • GCA and adenocarcinoma need oncology

    Goblet cell adenocarcinoma, colonic-type adenocarcinoma and signet ring disease behave more aggressively and need right hemicolectomy plus adjuvant chemotherapy.

How the diagnosis is made

From surprise histology to a specialist plan.

The steps a UK surgical or peritoneal malignancy team will normally follow after an appendicectomy that turns up something unexpected.

  1. 01

    Assessing

    Incidental histology after appendicectomy

    Most appendix cancers are found when a routinely removed appendix is examined under the microscope. The histology report is the starting point.

  2. 02

    Assessing

    Immunohistochemistry (IHC)

    Synaptophysin and chromogranin for NET, CDX2 and MUC2 for mucinous and colonic-type, beta-catenin and Ki-67 to grade behaviour.

  3. 03

    Assessing

    Symptom review and examination

    Palpable right iliac fossa mass, ascites, increasing abdominal girth or omental caking suggests peritoneal spread or pseudomyxoma peritonei.

  4. 04

    Confirming

    Staging imaging

    CT chest, abdomen and pelvis, an MRI abdomen where mucin mapping is needed, and DOTATATE PET-CT for neuroendocrine disease or FDG PET-CT for aggressive histology.

  5. 05

    Confirming

    Tumour markers

    CEA, CA 19-9 and CA 125 for mucinous and adenocarcinoma types. Serum chromogranin A and 24-hour urinary 5-HIAA for NET and suspected carcinoid syndrome.

  6. 06

    Referring

    Hereditary review

    Consider Lynch syndrome, MEN1 and NF1 where the pattern fits. A hereditary cancer panel and clinical genetics referral where indicated.

  7. 07

    Referring

    Urgent peritoneal malignancy MDT referral

    Any LAMN, HAMN, goblet cell adenocarcinoma, colonic-type adenocarcinoma or suspected pseudomyxoma peritonei needs referral to Basingstoke or Manchester.

Typical timeline: histology within days, reference-centre MDT within weeks.

Symptoms

What appendix cancer looks like.

Most patients have no symptoms until surgery. When symptoms do appear, they are often subtle - and easy to attribute to something benign.

  • Incidental finding

    By far the most common presentation. The appendix is removed for suspected appendicitis and the cancer is found on histology days later.

  • Right iliac fossa pain

    Chronic, grumbling right lower abdominal pain that behaves like appendicitis but does not settle.

  • Palpable mass

    A firm right iliac fossa mass on examination, sometimes with weight loss or a change in bowel habit.

  • Ascites and abdominal distension

    Increasing abdominal girth from mucinous ascites, often mistaken at first for weight gain or bloating.

  • Jelly belly (pseudomyxoma peritonei)

    Thick mucin coating the peritoneum, omental caking on scans and the classic gelatinous ascites at surgery.

  • Carcinoid syndrome (rare)

    Flushing, diarrhoea and, over time, right-sided cardiac valve fibrosis. Uncommon with an appendiceal primary but described.

  • Change in bowel habit

    Colonic-type adenocarcinoma of the appendix can behave like a right-sided colon cancer, with anaemia or altered bowel habit.

  • Red flag - unexplained ascites

    New ascites, omental caking or a rising CA 19-9 or CEA after appendicectomy needs urgent peritoneal malignancy review.

Treatment

How appendix cancer is treated in the UK.

Surgery is the backbone: appendicectomy or right hemicolectomy depending on histology. Peritoneal disease belongs at Basingstoke or Manchester for CRS plus HIPEC.

  • Appendicectomy alone

    Curative for a well-differentiated distal-tip NET under 1 cm with no invasion. Careful histology is essential to confirm.

  • Right hemicolectomy

    Standard for NET over 2 cm, invasive or mesoappendix-involved NET, goblet cell adenocarcinoma and colonic-type or signet ring adenocarcinoma.

  • CRS plus HIPEC

    Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and selected peritoneal spread. Delivered at Basingstoke and Manchester.

  • Adjuvant chemotherapy

    Capecitabine or FOLFOX for high-risk colonic-type or signet ring adenocarcinoma, guided by stage, margins and lymph node status.

  • Somatostatin analogues

    Octreotide LAR or lanreotide for functioning NET, carcinoid syndrome control and progression control in advanced well-differentiated disease.

  • Lu-177 DOTATATE (PRRT)

    Peptide receptor radionuclide therapy for advanced somatostatin-receptor-positive neuroendocrine tumours confirmed on DOTATATE PET.

  • Systemic therapy for GCA

    Goblet cell adenocarcinoma is treated more like an adenocarcinoma than a classical NET, with oncology-led systemic chemotherapy after resection.

  • Surveillance

    Interval CT, tumour markers (CEA, CA 19-9, CA 125) and, for NET, chromogranin A and 5-HIAA, on a schedule matched to histology and stage.

What this guide is based on

The sources behind every claim on this page.

International society consensus, UK national guidance and reference-centre pathways, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your surgeon, oncologist and peritoneal malignancy MDT know your histology and imaging and can tell you which parts apply to you. If in doubt, ask.

  • PSOGI (Peritoneal Surface Oncology Group International). Consensus on appendiceal mucinous neoplasms and pseudomyxoma peritonei.

  • ENETS (European Neuroendocrine Tumour Society). Guidelines on appendiceal neuroendocrine neoplasms.

  • NICE. Neuroendocrine tumours and colorectal cancer guidance (relevant sections).

  • Basingstoke Peritoneal Malignancy Institute and The Christie, Manchester. UK national referral pathways for CRS and HIPEC.

Red flags

When appendix cancer needs urgent attention.

Rare, high-consequence signals that should trigger same-week imaging and a call to the peritoneal malignancy MDT.

  • Unexplained ascites

    New ascites or increasing abdominal girth after an appendicectomy needs prompt imaging and specialist review to exclude pseudomyxoma peritonei.

  • Rising tumour markers

    A rising CEA or CA 19-9 during surveillance after appendix cancer surgery warrants urgent cross-sectional imaging and MDT discussion.

  • Carcinoid syndrome features

    Flushing, diarrhoea and wheeze, especially with a known NET, need urgent biochemical workup (5-HIAA, chromogranin A) and echocardiogram.

  • Bowel obstruction

    A patient with known peritoneal disease who develops obstruction needs urgent surgical assessment at a peritoneal malignancy centre.

  • Perforated LAMN at appendicectomy

    Any mucin outside the appendix at the time of surgery is a red flag for future pseudomyxoma and mandates specialist referral.

  • Signet ring or high-grade histology

    Signet ring and high-grade mucinous or adenocarcinoma histology behaves aggressively and needs early oncology and peritoneal malignancy input.

  • Family history suggestive of Lynch

    Multiple early-onset colorectal or endometrial cancers in the family, especially with MSI-high histology, warrant genetics referral.

  • Right-sided heart symptoms

    Breathlessness or peripheral oedema in a patient with a functioning NET raises concern for carcinoid heart disease and needs cardiology review.

  • Rapid abdominal distension

    Rapidly rising girth, satiety and weight loss suggest advancing peritoneal disease and needs same-week imaging.

Living with it

A rare cancer, a very specific pathway.

Four practical points that make the biggest difference after an appendix cancer diagnosis - centre choice, surveillance, symptom reporting and support networks.

A quiet reminder

Rare disease deserves reference care.

The centres that see hundreds of these cases a year get better results than the ones that see two. Ask for the referral early.

  1. 01 Team

    Insist on the right centre

    Peritoneal appendix cancer belongs at a national reference centre. Ask for early referral to Basingstoke or Manchester rather than local generalist care.

  2. 02 Follow-up

    Keep surveillance appointments

    Interval CT, tumour markers and NET biomarkers are how quiet recurrence is caught early. Diary them and do not skip them.

  3. 03 Symptoms

    Report new symptoms early

    New pain, bloating, ascites or bowel change after treatment deserves a call to the CNS or MDT rather than watchful waiting at home.

  4. 04 Support

    Use peritoneal-specific support

    Charities like Pseudomyxoma Survivor and the UK NET Patient Foundation understand these rare cancers better than general services.

Frequently asked

Everything we get asked about appendix cancer.

Quick answers on NET, LAMN, goblet cell adenocarcinoma, pseudomyxoma peritonei and CRS plus HIPEC.

  • What is appendix cancer?

    Appendix cancer is a group of rare tumours arising in the vermiform appendix. The commonest is a neuroendocrine tumour (NET). Others include goblet cell adenocarcinoma, low-grade and high-grade appendiceal mucinous neoplasms (LAMN and HAMN), colonic-type adenocarcinoma and signet ring adenocarcinoma. Each behaves differently and needs a different plan.

  • How is it usually found?

    Most cases are incidental. Someone has an appendicectomy for suspected appendicitis, and the pathologist finds a cancer in the removed appendix days later. Less often, patients present with a right iliac fossa mass, chronic pain or the distended jelly belly of pseudomyxoma peritonei.

  • Is a small neuroendocrine tumour of the appendix serious?

    A well-differentiated neuroendocrine tumour smaller than 1 cm, sitting at the tip of the appendix, with no invasion of the base or mesoappendix, is usually cured by appendicectomy alone. Tumours over 2 cm, high-grade lesions or those with invasion need a right hemicolectomy and oncology follow-up.

  • What is pseudomyxoma peritonei?

    Pseudomyxoma peritonei (PMP) is a slow-spreading disease where mucin-producing cells from a ruptured appendiceal mucinous neoplasm coat the peritoneal surfaces. It causes progressive abdominal distension, ascites and the characteristic jelly belly. Modern treatment with cytoreductive surgery plus HIPEC gives 5-year survival of 60 to 90 percent for low-grade disease.

  • What is CRS plus HIPEC?

    CRS stands for cytoreductive surgery: methodically removing all visible peritoneal disease. HIPEC is hyperthermic intraperitoneal chemotherapy, where warmed chemotherapy is circulated inside the abdomen at the end of surgery. In the UK it is delivered at Basingstoke and Manchester and it is the treatment that has transformed outcomes for pseudomyxoma peritonei.

  • Do I need genetic testing?

    Not everyone, but genetics should be considered when the pattern fits: young age, multiple primaries, a strong family history of colorectal or endometrial cancer (Lynch syndrome), features of MEN1 or NF1, or MSI-high histology. A hereditary cancer panel and clinical genetics referral can guide surveillance for you and your family.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.